blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4071163

EP4071163 - NUCLEIC ACID COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING SAME [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  09.09.2022
Database last updated on 16.09.2024
FormerThe international publication has been made
Status updated on  06.08.2021
Most recent event   Tooltip02.09.2024The date on which the examining division becomes responsible, has been established 
02.09.2024Amendment by applicant 
Applicant(s)For all designated states
Eisai R&D Management Co., Ltd.
4-6-10 Koishikawa
Bunkyo-ku
Tokyo 112-8088 / JP
[N/P]
Former [2022/44]For all designated states
Eisai R&D Management Co., Ltd.
4-6-10 Koishikawa Bunkyo-ku
Tokyo 112-8088 / JP
Former [2022/41]For all designated states
Eisai R&D Management Co., Ltd
4-6-10 Koishikawa
Bunkyo-ku, Tokyo 112-8088 / JP
Inventor(s)01 / SUZUKI Yuta
C/O Eisai Co., Ltd. Tsukuba Research Laboratories
5-1-3 Tokodai
Tsukuba-shi, Ibaraki 300-2635 / JP
02 / YAMAZAKI Kazuto
C/O Eisai Co., Ltd. Tsukuba Research Laboratories
5-1-3 Tokodai
Tsukuba-shi, Ibaraki 300-2635 / JP
03 / KUBARA Kenji
C/O Eisai Co., Ltd. Tsukuba Research Laboratories
5-1-3 Tokodai
Tsukuba-shi, Ibaraki 300-2635 / JP
04 / TAMURA Tomohiko
c/o Public University Corporation Yokohama City
University, 3-9, Fukuura, Kanazawa-ku
Yokohama-shi, Kanagawa 236-0004 / JP
05 / KUROTAKI Daisuke
c/o NATIONAL UNIVERSITY CORPORATION KUMAMOTO
UNIVERSITY, 39-1, Kurokami 2-chome, Chuo-ku
Kumamoto-shi, Kumamoto 860-8555 / JP
 [2022/41]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2022/41]
Application number, filing date21747841.128.01.2021
[2022/41]
WO2021JP03085
Priority number, dateJP2020001399730.01.2020         Original published format: JP 2020013997
[2022/41]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021153687
Date:05.08.2021
Language:JA
[2021/31]
Type: A1 Application with search report 
No.:EP4071163
Date:12.10.2022
Language:EN
[2022/41]
Search report(s)International search report - published on:JP05.08.2021
(Supplementary) European search report - dispatched on:EP21.02.2024
ClassificationIPC:A61K47/54, A61K48/00, A61K31/7088, C07K9/00, C12N15/11, C12N15/113
[2024/12]
CPC:
C12N15/113 (EP,US); C12N15/111 (EP,US); A61K47/549 (EP,US);
C12N2310/11 (EP); C12N2310/14 (EP); C12N2310/315 (EP,US);
C12N2310/351 (EP,US) (-)
C-Set:
C12N2310/321, C12N2310/3521 (EP);
C12N2310/322, C12N2310/3533 (EP);
C12N2310/341, C12N2310/3231 (EP)
Former IPC [2022/41]C07K9/00, A61K31/7088, A61K47/54, A61K48/00, C12N15/113
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/41]
TitleGerman:NUKLEINSÄUREKOMPLEX UND DIESEN ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNG[2022/41]
English:NUCLEIC ACID COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING SAME[2022/41]
French:COMPLEXE D'ACIDE NUCLÉIQUE ET COMPOSITION PHARMACEUTIQUE LE CONTENANT[2022/41]
Entry into regional phase06.07.2022Translation filed 
06.07.2022National basic fee paid 
06.07.2022Search fee paid 
06.07.2022Designation fee(s) paid 
06.07.2022Examination fee paid 
Examination procedure06.07.2022Examination requested  [2022/41]
27.08.2024Amendment by applicant (claims and/or description)
27.08.2024Date on which the examining division has become responsible
Fees paidRenewal fee
25.01.2023Renewal fee patent year 03
25.01.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XA]WO2018004004  (KYOWA HAKKO KIRIN CO LTD [JP]) [X] 1,4-12 * compound 50 on page 123 * * compound 67 on page 128 * * compound 147 on page 155 * * compound 146 on page 157 * * compound 169 on page 160 * * compound 168 on page 162 * * paragraph [0131] * * paragraph [0290] * * table 9 on page 129 * [A] 2;
 [XAI]WO2018132432  (ARROWHEAD PHARMACEUTICALS INC [US]) [X] 1,3,7-12 * table 7 * * page 76, line 5 - line 8 * * page 94, line 5 - line 7 * * page 95, line 24 - line 31 * * page 111, line 1 - line 2 * [A] 2 [I] 4-6;
 [XAI]  - THAZHA P. PRAKASH ET AL, "Comprehensive Structure-Activity Relationship of Triantennary N -Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes", JOURNAL OF MEDICINAL CHEMISTRY, US, (20160324), vol. 59, no. 6, doi:10.1021/acs.jmedchem.5b01948, ISSN 0022-2623, pages 2718 - 2733, XP055394434 [X] 1,4,6,10-12 * figure 2 * * figure 4 * * figure 9 * * page 2724, column left, paragraph 4 * * page 2724, column right, paragraph 2 * [A] 2 [I] 5,7-9

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.5b01948
International search[XY]WO2015042447  (ISIS PHARMACEUTICALS INC [US]) [X] 2,15-23 * 1-235, p.50, 1.8 to p. 76, 1.13, Ex.29, Ex32, Ex33, Ex.37 * [Y] 2,8-23;
 [XY]JP2016526874  [X] 2,15-23 * 1-242, 507-509,528-533 * [Y] 2,8-23;
 [XY]WO2018140920  (ARROWHEAD PHARMACEUTICALS INC [US]) [X] 2,12,16-23 * 1-25, p.83, 1.5 to p.87, 1.11, p.93 * [Y] 2,8-23;
 [A]WO2018187515  (AVIDEA TECH INC [US], et al) [A] 1,3-7,15-23* 341, 359, 363, 30, 32, 35,37, 41-43 *
by applicantWO2009073809
 WO2013075035
 WO2014179620
 WO2015105083
 WO2016100401
 WO2018004004
    - Nature Reviews Drug Discovery, (20090000), vol. 8, pages 129 - 138
    - J.Am. Chem. Soc., (20140000), vol. 136, pages 16958 - 16961
    - Nucleic Acids Research, (20190000), vol. 47, no. 3, pages 1082 - 1096
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.